Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2005

Open Access 01-12-2005 | Primary research

U94 alters FN1 and ANGPTL4 gene expression and inhibits tumorigenesis of prostate cancer cell line PC3

Authors: Ekwere T Ifon, Alan LY Pang, Warren Johnson, Kathleen Cashman, Sharon Zimmerman, Sumitra Muralidhar, Wai-Yee Chan, John Casey, Leonard Jason Rosenthal

Published in: Cancer Cell International | Issue 1/2005

Login to get access

Abstract

Background

Insensitivity of advanced-stage prostate cancer to androgen ablation therapy is a serious problem in clinical practice because it is associated with aggressive progression and poor prognosis. Targeted therapeutic drug discovery efforts are thwarted by lack of adequate knowledge of gene(s) associated with prostate tumorigenesis. Therefore there is the need for studies to provide leads to targeted intervention measures. Here we propose that stable expression of U94, a tumor suppressor gene encoded by human herpesvirus 6A (HHV-6A), could alter gene expression and thereby inhibit the tumorigenicity of PC3 cell line. Microarray gene expression profiling on U94 recombinant PC3 cell line could reveal genes that would elucidate prostate cancer biology, and hopefully identify potential therapeutic targets.

Results

We have shown that stable expression of U94 gene in PC3 cell line inhibited its focus formation in culture, and tumorigenesis in nude mice. Moreover gene expression profiling revealed dramatic upregulation of FN 1 (fibronectin, 91 ± 16-fold), and profound downregulation of ANGPTL 4 (angiopoietin-like-4, 20 ± 4-fold) in U94 recombinant PC3 cell line. Quantitative real-time polymerase chain reaction (QRT-PCR) analysis showed that the pattern of expression of FN 1 and ANGPTL 4 mRNA were consistent with the microarray data. Based on previous reports, the findings in this study implicate upregulation of FN 1 and downregulation of ANGPTL 4 in the anti tumor activity of U94. Genes with cancer inhibitory activities that were also upregulated include SERPINE 2 (serine/cysteine protease inhibitor 2, 7 ± 1-fold increase) and ADAMTS 1 (a disintegrin-like and metalloprotease with thrombospondin type 1 motif, 7 ± 2-fold increase). Additionally, SPUVE 23 (serine protease 23) that is pro-tumorigenic was significantly downregulated (10 ± 1-fold).

Conclusion

The dramatic upregulation of FN 1 and downregulation of ANGPTL 4 genes in PC3 cell line stably expressing U94 implicate up-regulation of FN 1 and downregulation of ANGPTL 4 in anti tumor activity of U94. Further studies are necessary to determine functional roles of differentially expressed genes in U94 recombinant PC3 cell line, and hopefully provide leads to potential therapeutic targets in prostate cancer.
Appendix
Available only for authorised users
Literature
1.
2.
Ficazzola MA, Taneja SS: Prospects for gene therapy in human prostate cancer. Molecular Medicine Today. 1998, 4: 494-504. 10.1016/S1357-4310(98)01334-3.CrossRefPubMed
3.
Buttyan R, Shabsigh A, Perlman H, Colombel M: Regulation of Apoptosis in the Prostate Gland by Androgenic Steroids. Trends Endocrinol Metab. 1999, 10: 47-54. 10.1016/S1043-2760(98)00104-0.CrossRefPubMed
4.
Chakravarti A, Zhai GG: Molecular and genetic prognostic factors of prostate cancer. World J Urol. 2003, 21: 265-274. 10.1007/s00345-003-0362-z.CrossRefPubMed
5.
Karan D, Lin M, Johansson SL, Batra SK: Current Status of the Molecular Genetics of Human Prostatic Adenocarcinomas. Int J Cancer. 2003, 103: 285-293. 10.1002/ijc.10813.CrossRefPubMed
6.
Abate-Shen C, Shen MM: Molecular genetics of prostate cancer. Genes and Dev. 2000, 14: 2410-2434. 10.1101/gad.819500.CrossRefPubMed
7.
Kumazawa T, Tsuchiya N, Wang L, Sato K, Kamoto T, Ogawa O, Nakamura A, Kato T, Habuchi T: Microsatellite polymorphism of steroid hormone synthesis gene CYP11A1 is associated with advanced prostate cancer. Int J Cancer. 2004, 110: 140-144. 10.1002/ijc.20070.CrossRefPubMed
8.
Flaherty KT, Malkowicz SB, Vaughn DJ: Phase I study of weekly liposome-encapsulated doxorubicin in patients with advanced, androgen-independent prostate cancer. Am J Clin Oncol. 2004, 27: 136-139. 10.1097/01.coc.0000054888.02055.4E.CrossRefPubMed
9.
Joshi B, Li L, Taffe BG, Zhu Z, Wahl S, Tian H, Ben-Josef E, Taylor JD, Porter AT, Tang DG: Apoptosis Induction by a Novel Anti-Prostate Cancer Compound, BMD188 (a Fatty Acid-containing Hydroxamic Acid), Requires the Mitochondrial Respiratory Chain. Cancer Res. 1999, 59: 4343-4355.PubMed
10.
Goodin S, Rao KV, DiPaola RS: State-of-the-Art Treatment of Metastatic Hormone-Refractory Prostate Cancer. Oncologist. 2002, 7: 360-370. 10.1634/theoncologist.7-4-360.CrossRefPubMed
11.
Gulley J, Dahut W: Novel clinical trials in androgen-independent prostate cancer. Clin Prostate Cancer. 2002, 1: 51-57.CrossRefPubMed
12.
Nimmanapalli R, Perkins CL, Orlando M, O'Bryan E, Nguyen D, Bhalla KN: Pretreatment with Paclitaxel Enhances Apo-2 Ligand/Tumor Necrosis Factor- related Apoptosis-inducing Ligand-induced Apoptosis of Prostate Cancer Cells by Inducing Death Receptors 4 and 5 Protein Levels. Cancer Res. 2001, 61: 759-763.PubMed
13.
Chay CH, Cooper CC, Hellerstedt BA, Pienta KJ: Antimetastatic drugs in prostate cancer. Clin Prostate Cancer. 2002, 1: 14-19.CrossRefPubMed
14.
Allay JA, Steiner MS, Zhang Y, Reed CP, Cockroft J, Lu Y: Adenovirus p16 gene therapy for prostate cancer. World J Urol. 2000, 18: 111-120. 10.1007/s003450050182.CrossRefPubMed
15.
Arlen PM, Figg WD, Gulley J, Cox MC, Linehan WM, Dahut W: National Cancer Institute intramural approach to advanced prostate cancer. Clin Prostate Cancer. 2002, 1: 153-162.CrossRefPubMed
16.
Raghow S, Hooshdaran MZ, Katiyar S, Steiner MS: Toremifene prevents prostate cancer in the transgenic adenocarcinoma of mouse prostate model. Cancer Res. 2002, 62: 1370-1376.PubMed
17.
Steiner MS, Wang Y, Zhang Y, Zhang X, Lu Y: p16/MTS1/INK4A suppresses prostate cancer by both pRb dependent and independent pathways. Oncogene. 2000, 19: 1297-1306. 10.1038/sj.onc.1203428.CrossRefPubMed
18.
Sternberg C: Overview of international collaborative group prostate cancer trials. Crit Rev Oncol Hematol. 2002, 43: 153-158.CrossRefPubMed
19.
Collis SJ, Khater K, DeWeese TL: Novel therapeutic strategies in prostate cancer management using gene therapy in combination with radiation therapy. World J Urol. 2003, 21: 275-289. 10.1007/s00345-003-0363-y.CrossRefPubMed
20.
Timme TL, Satoh T, Tahir SA, Wang H, Teh BS, Butler EB, Miles BJ, Amato RJ, Kadmon D, Thompson TC: Therapeutic targets for metastatic prostate cancer. Curr Drug Targets. 2003, 4: 251-261. 10.2174/1389450033491127.CrossRefPubMed
21.
Thompson BJ, Efstathiou S, Honess RW: Acquisition of the human adeno-associated virus type-2 rep gene by human herpesvirus type-6. Nature. 1991, 351: 78-80. 10.1038/351078a0.CrossRef
22.
Araujo JC, Doniger J, Kashanchi F, Hermonat PL, Thompson J, Rosenthal LJ: Human Herpesvirus 6A suppresses both transformations by H-ras and Human Immunodeficiency Virus type 1 promoters. J Virol. 1995, 69: 4933-4940.PubMedCentralPubMed
23.
Mori Y, Dhepakson P, Shimamoto T, Ueda K, Gomi Y, Tani H, Matsuura Y, Yamanishi K: Expression of human herpesvirus 6B rep within infected cells and binding of its gene product to the TATA-Binding protein in vitro and in vivo. J Virol. 2000, 74: 6096-6104. 10.1128/JVI.74.13.6096-6104.2000.PubMedCentralCrossRefPubMed
24.
Dhepakson P, Mori Y, Jiang YB, Huang HL, Akkapaiboon P, Okuno T, Yamanishi K: Human herpesvirus-6 rep/U94 gene product has single-stranded DNA-binding activity. J Gen Virol. 2002, 83: 847-854.CrossRefPubMed
25.
Rotola A, Ravaioli T, Gonelli A, Dewhurst S, Cassai E, Di Luca D: U94 of human herpesvirus 6 is expressed in latently infected peripheral blood mononuclear cells and blocks viral gene expression in transformed lymphocytes in culture. Proc Natl Acad Sci USA. 1998, 95: 13911-13916. 10.1073/pnas.95.23.13911.PubMedCentralCrossRefPubMed
26.
Turner S, DiLuca D, Gompels UA: Characterization of a human herpesvirus 6 variant A 'amplicon' and replication modulation by U94-Rep 'latency gene'. Journal of Virological Methods. 2002, 105: 331-341. 10.1016/S0166-0934(02)00130-1.CrossRefPubMed
27.
Gompels UA, Nicholas J, Lawrence G, Jones M, Thomson BJ, Martin ME, Efstathiou S, Craxton M, Macaulay HA: The DNA sequence of human herpesvirus-6: structure, coding content, and genome evolution. Virology. 1995, 209: 29-51. 10.1006/viro.1995.1228.CrossRefPubMed
28.
Thomson BJ, Weindler FW, Gray D, Schwaab V, Heilbronn R: Human herpesvirus 6 (HHV-6) is a helper virus for adeno-associated virus type 2 (AAV-2) and the AAV-2 rep gene homologue in HHV-6 can mediate AAV-2 DNA replication and regulate gene expression. Virology. 1994, 204: 304-311. 10.1006/viro.1994.1535.CrossRefPubMed
29.
Araujo JC, Doniger J, Stöppler H, Sadaie MR, Rosenthal LJ: Cell lines containing and expressing the human herpesvirus 6A ts gene are protected from both H-ras and BPV-1 transformation. Oncogene. 1997, 14: 937-943. 10.1038/sj.onc.1200899.CrossRefPubMed
30.
Kibel AS, Faith DA, Bova GS, Isaacs WB: Loss of heterozygosity at 12P12-13 in primary and metastatic prostate adenocarcinoma. J Urol. 2000, 164: 192-196. 10.1097/00005392-200007000-00059.CrossRefPubMed
31.
Guo Y, Sklar GN, Borkowski A, Kyprianou N: Loss of the cyclin-dependent kinase inhibitor p27(Kip1) protein in human prostate cancer correlates with tumor grade. Clin Cancer Res. 1997, 3: 2269-2274.PubMed
32.
Tsihlias J, Kapusta LR, DeBoer G, Morava-Protzner I, Zbieranowski I, Bhattacharya N, Catzavelos GC, Klotz LH, Slingerland JM: Loss of cyclin-dependent kinase inhibitor p27Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma. Cancer Res. 1998, 58: 542-548.PubMed
33.
Yang RM, Naitoh J, Murphy M, Wang HJ, Phillipson J, deKernion JB, Loda M, Reiter RE: Low p27 expression predicts poor disease-free survival in patients with prostate cancer. J Urol. 1998, 159: 941-945. 10.1097/00005392-199803000-00088.CrossRefPubMed
34.
Park MS, Rosai J, Nguyen HT, Capodieci P, Cordon-Cardo C, Koff A: p27 and Rb are on overlapping pathways suppressing tumorigenesis in mice. Proc Natl Acad Sci USA. 1999, 96: 6382-6387. 10.1073/pnas.96.11.6382.PubMedCentralCrossRefPubMed
35.
Chi SG, deVere White RW, Muenzer JT, Gumerlock PH: Frequent alteration of CDKN2 (p16(INK4A)/MTS1) expression in human primary prostate carcinomas. Clin Cancer Res. 1997, 3: 1889-1897.PubMed
36.
Jarrard D, Modder J, Fadden P, Fu V, Sebree L, Heisey D, Schwarze S, Friedl A: Alterations in the p16/pRb cell cycle checkpoint occur commonly in primary and metastatic human prostate cancer. Cancer Lett. 2002, 185: 191-10.1016/S0304-3835(02)00282-3.CrossRefPubMed
37.
Jarrard DF, Sarkar S, Shi Y, Yeager TR, Magrane G, Kinoshita H, Nassif N, Meisner L, Newton MA, Waldman FM, Reznikoff CA: p16/pRb pathway alterations are required for bypassing senescence in human prostate epithelial cells. Cancer Res. 1999, 59: 2957-2964.PubMed
38.
Alexander K, Hinds PW: Requirement for p27(KIP1) in retinoblastoma protein-mediated senescence. Mol Cell Biol. 2001, 21: 3616-3631. 10.1128/MCB.21.11.3616-3631.2001.PubMedCentralCrossRefPubMed
39.
Colombel M, Symmans F, Gil S, O'Toole KM, Chopin D, Benson M, Olsson CA, Korsmeyer S, Buttyan R: Detection of the apoptosis-suppressing oncoprotein Bcl-2 in hormone-refractory human prostate cancers. Am J Pathol. 1993, 143: 390-400.PubMedCentralPubMed
40.
Apakama I, Robinson MC, Walter NM, Charlton RG, Royds JA, Fuller CE, Neal DE, Hamdy FC: Bcl-2 overexpression combined with p53 protein accumulation correlates with hormone-refractory prostate cancer. Brit J Cancer. 1996, 74: 1258-1262.PubMedCentralCrossRefPubMed
41.
Furuya Y, Krajewski S, Epstein JI, Reed JC, Isaacs JT: Expression of Bcl-2 and the progression of human and rodent prostatic cancers. Clin Cancer Res. 1996, 2: 389-398.PubMed
42.
McDonnell TJ, Navone NM, Troncoso P, Pisters LL, Conti C, von Eschenbach AC, Brisbay S, Logothetis CJ: Expression of bcl-2 oncoprotein and p53 protein accumulaion in bone marrow metastases of androgen independent prostate cancer. J Urol. 1997, 157: 569-574. 10.1097/00005392-199702000-00042.CrossRefPubMed
43.
Chaudhary KS, Abel PD, Lalani EN: Role of the Bcl-2 gene family in prostate cancer progression and its implications for therapeutic intervention. Environ Health Perspect. 1999, 107 (Suppl 1): 49-57.PubMedCentralCrossRefPubMed
44.
Buttyan R, Sawczuk IS, Benson MC, Siegal JD, Olsson CA: Enhanced expression of the c-myc protooncogene in high-grade human prostate cancers. Prostate. 1987, 11: 327-337.CrossRefPubMed
45.
Phillips MEA, Ferro MA, Smith PJB, Davies P: Intranuclear androgen receptor deployment and protooncogene expression in human diseased prostate. Urol Int. 1987, 42: 115-119.CrossRefPubMed
46.
Nag A, Smith RG: Amplification, rearrangement, and elevated expression of c-myc in the human prostatic carcinoma cell line LNCaP. Prostate. 1989, 15: 115-122.CrossRefPubMed
47.
48.
Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K, Pienta KJ, Rubin MA, Chinnaiyan AM: Delineation of prognostic biomarkers in prostate cancer. Nature. 2001, 412: 822-826. 10.1038/35090585.CrossRefPubMed
49.
Muralidhar S, Doniger J, Mendelson E, Araujo JC, Kashanchi F, Azumi N, Brady JN, Rosenthal LJ: Human cytomegalovirus mtrII oncoprotein binds to p53 and down-regulates p53-activated transcription. J Virol. 1996, 70: 8691-8700.PubMedCentralPubMed
50.
Le-Jan S, Amy C, Cazes A, Monnot C, Lamande N, Favier J, Philippe J, Siboney M, Gasc JM, Corvol P, Germain S: Angiopoietin-like 4 is a proangiogenic factor produced during ischemia and in conventional renal cell carcinoma. Am J Pathol. 2003, 162: 1521-1528.PubMedCentralCrossRefPubMed
51.
Yi M, Ruoslahti E: A fibronectin fragment inhibits tumor growth, angiogenesis, and metastasis. Proc Natl Acad Sci USA. 2001, 98: 620-624. 10.1073/pnas.98.2.620.PubMedCentralCrossRefPubMed
52.
Zhang GM, Yang Y, Huang B, Xiao H, Li D, Feng ZH: Experimental study on therapeutic effect of in vivo expression of Cell I-Hep II recombinant polypeptide of fibronectin on murine H22 hepatocellular carcinoma. World J Gastroenterol. 2003, 9: 1940-1945.PubMed
53.
Yi M, Sakai T, Fassler R, Ruoslahti E: Antiangiogenic proteins require plasma fibronectin or vitronectin for in vivo activity. Proc Natl Acad Sci USA. 2003, 100: 11435-11438. 10.1073/pnas.1635112100.PubMedCentralCrossRefPubMed
54.
Pasqualini R, Bourdoulous S, Koivunen E, Woods VL, Ruoslahti EA: Polymeric form of fibronectin has antimetastatic effects against multiple tumor types. Nat Med. 1996, 2: 1197-1203. 10.1038/nm1196-1197.CrossRefPubMed
55.
Hynes RO: The dynamic dialogue between cells and matrices: implications of fibronectin's elasticity. Proc Natl Acad Sci USA. 1999, 96: 2588-2590. 10.1073/pnas.96.6.2588.PubMedCentralCrossRefPubMed
56.
Schwarzbauer JE: Identification of the fibronectin sequences required for assembly of a fibrillar matrix. J Cell Biol. 1991, 113: 1463-1473. 10.1083/jcb.113.6.1463.CrossRefPubMed
57.
Hocking DC, Sottile J, McKeown-Longo PJ: Fibronectin's III-1 module contains a conformation-dependent binding site for the amino-terminal region of fibronectin. J Biol Chem. 1994, 269: 19183-19191.PubMed
58.
Aguirre KM, McCormick RJ, Schqarzbauer JE: Fibronectin self-association is mediated by complementary sites within the amino-terminal one-third of the molecule. J Biol Chem. 269: 27863-27868.
59.
Briknarovà K, Åkerman ME, Hoyt DW, Ruoslahti E, Ely KR: Anastellin, an FN 3 Fragment with Fibronectin Polymerization Acitivity, Resembles Amyloid Fibril Precursors. J Mol Biol. 2003, 332: 205-215. 10.1016/S0022-2836(03)00890-8.CrossRefPubMed
60.
Pickford AR, Smith SP, Staunton D, Boyd J, Campbell ID: The hairpin structure of the 6F11F22F2 fragment from human fibronectin enhances gelatin binding. The EMBO Journal. 2001, 20: 1519-1529. 10.1093/emboj/20.7.1519.PubMedCentralCrossRefPubMed
61.
Clark EA, Brugge JS: Integrins and signal transduction pathways: the road taken. Science. 1995, 268: 233-239.CrossRefPubMed
62.
Brenner KA, Corbett SA, Schwarzbauer JE: Regulation of fibronectin matrix assembly by activated Ras in transformed cells. Oncogene. 2000, 19: 3156-3163. 10.1038/sj.onc.1203626.CrossRefPubMed
63.
Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995, 1: 27-31. 10.1038/nm0195-27.CrossRefPubMed
64.
65.
Varner JA: The role of vascular cell integrins alpha v beta 3 and alpha v beta 5 in angiogenesis. EXS. 1997, 79: 361-90.PubMed
66.
Ruoslahti e: The RGD story: a personal account. Matrix Biology. 2003, 22: 459-465. 10.1016/S0945-053X(03)00083-0.CrossRefPubMed
67.
Hynes RO: A reevaluation of integrins as regulators of angiogenesis. Nat Med. 2002, 8: 918-921. 10.1038/nm0902-918.CrossRefPubMed
68.
Vitale M, Matola TD, Rossi G, Laezza C, Fenzi G, Bifulco M: Prenyltransferase inhibitors induce apoptosis in proliferating thyroid cells through a p53-Independent, CrmA-Sensitive, and caspase-3-like protease-dependent mechanism. Endocrinology. 1999, 140: 698-704. 10.1210/en.140.2.698.PubMed
69.
Kuno K, Terashima Y, Matsushima K: ADAMTS-1 is an active metalloproteinase associated with the extracellular matrix. J Biol Chem. 1999, 274: 18821-18826. 10.1074/jbc.274.26.18821.CrossRefPubMed
70.
Shindo T, Kurihara H, Kuno K, Yokoyama H, Wada T, Kurihara Y, Imai T, Wang Y, Ogata M, Nishimatsu H, Moriyama N, Oh-hashi Y, Morita H, Ishikawa T, Nagai R, Yazaki Y, Matsushima K: ADAMTS-1: a metalloproteinase-disintegrin essential for normal growth, fertility, and organ morphology and function. J Clin Invest. 2000, 105: 1345-1352.PubMedCentralCrossRefPubMed
71.
Vazquez F, Hastings G, Ortega MA, Lane TF, Oikemus S, Lombardo M, Iruela-Arispe ML: METH-1, a human ortholog of ADAMTS-1, and METH-2 are members of a new family of proteins with angio-inhibitory activity. J Biol Chem. 1999, 274: 23349-23357. 10.1074/jbc.274.33.23349.CrossRefPubMed
72.
Pineiro-Sanchez ML, Goldstein LA, Dodt J, Howard L, Yeh Y, Chen W: Identification of the 170-kDa Melanoma membrane-bound gelatinase (seprase) as a serine integral membrane protease. J Biol Chem. 1997, 272: 7595-7601. 10.1074/jbc.272.12.7595.CrossRefPubMed
73.
Vacca A, Ria R, Presta M, Ribatti D, Iurlaro M, Merchionne F, Tanghetti E, Dammacco F: alpha (v) beta (3) integrin engagement modulates cell adhesion, proliferation, and protease secretion in human lymphoid tumor cells. Exp Hematol. 2001, 29: 993-1003. 10.1016/S0301-472X(01)00674-9.CrossRefPubMed
74.
Abeysinghe HR, Cao Q, Xu J, Pollock S, Veyberman Y, Guckert NL, Keng P, Wang N: THY1 expression is associated with tumor suppression of human ovarian cancer. Cancer Genetics and Cytogenetics. 2002, 143: 125-132. 10.1016/S0165-4608(02)00855-5.CrossRef
75.
Rapp JC, Krug LT, Inoue N, Dambaugh TR, Pellett PE: U94 the human herpesvirus 6 homolog of the Parvovirus nonstructural gene, is highly conserved among isolates and is expressed at low mRNA levels as a spliced transcript. Virology. 2000, 268: 504-516. 10.1006/viro.1999.0163.CrossRefPubMed
76.
Beheshti B, Park PC, Sweet JM, Trachtenberg J, Jewett MA, Squire JA: Evidence of chromosomal instability in prostate cancer determined by spectral karyotyping (SKY) and interphase fish analysis. Neoplasia. 2001, 3: 62-69. 10.1038/sj.neo.7900125.PubMedCentralCrossRefPubMed
77.
Olnes MI, Kurl RN: Isolation of nuclear extracts from fragile cells: a simplified procedure applied to thymocytes. Biotechniques. 1994, 17: 828-829.PubMed
78.
Muralidhar S, Pumfery AM, Hassani M, Sadaie MR, Kishishita M, Brady JN, Doniger J, Medveczky P, Rosenthal LJ: Identification of kaposin (open reading frame K12) as a human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus) transforming gene. J Virol. 1998, 72: 4980-4988.PubMedCentralPubMed
79.
Pang AL, Taylor HC, Johnson W, Alexander S, Chen Y, Su YA, Li X, Ravindranath N, Dvm M, Rennert OM, Chan WY: Identification of differentially expressed genes in mouse spermatogenesis. J Androl. 2003, 24: 899-911.PubMed
Metadata
Title
U94 alters FN1 and ANGPTL4 gene expression and inhibits tumorigenesis of prostate cancer cell line PC3
Authors
Ekwere T Ifon
Alan LY Pang
Warren Johnson
Kathleen Cashman
Sharon Zimmerman
Sumitra Muralidhar
Wai-Yee Chan
John Casey
Leonard Jason Rosenthal
Publication date
01-12-2005
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2005
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/1475-2867-5-19

Other articles of this Issue 1/2005

Cancer Cell International 1/2005 Go to the issue

Primary research

Melanoma Inhibitory Activity (MIA) increases the invasiveness of pancreatic cancer cells

Primary research

Endothelial cell pseudopods and angiogenesis of breast cancer tumors

Review

ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal

Primary research

Rapid in vivo Taxotere quantitative chemosensitivity response by 4.23 Tesla sodium MRI and histo-immunostaining features in N-Methyl-N-Nitrosourea induced breast tumors in rats

Primary research

Specific distribution of overexpressed aurora B kinase in interphase normal epithelial cells

Primary research

Multidrug Resistance-Associated Protein 1 (MRP1) mediated vincristine resistance: effects of N-acetylcysteine and Buthionine Sulfoximine
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits